Cellular models for human cardiomyopathy: What is the best option?

doi:10.4330/wjc.v11.i10.221

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8397)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

493

WORD

176

HTML

4798

Figures (1-3)

378

Tables (1-3)

266

Sum=6111

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

778

Download

1508

Sum=2286

Oct 26, 2019 (publication date) through Jan 3, 2025

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Cardiology

ISSN

1949-8462

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Cardiol. Oct 26, 2019; 11(10): 221-235
Published online Oct 26, 2019. doi: 10.4330/wjc.v11.i10.221

Table 3 Advantages and disadvantages of different cell types for modeling disease in vitro

Properties	Fibroblasts	iPSCs
Proliferation capacity	+	++
Self-renewal	No	Yes
Longevity	Limited	Unlimited
Differentiation	No	Yes
Metabolism	Quiescent	Energetic
Acquisition	Easy	Difficult
Cost	+	+++
Ease of maintenance	Simple	Difficult
Necessary expertise	Low	High
Disease modeling	+	++
Structure	Single elongated cells	Round colonies/beating CM sheets
Maturation	Not applicable	Required for CM

iPSCs: Induced pluripotent stem cells; CM: Cardiomyopathy.

Citation: Jimenez-Tellez N, Greenway SC. Cellular models for human cardiomyopathy: What is the best option? World J Cardiol 2019; 11(10): 221-235
URL: https://www.wjgnet.com/1949-8462/full/v11/i10/221.htm
DOI: https://dx.doi.org/10.4330/wjc.v11.i10.221